• Updated insulin treatment sections including new bolus and basal insulin formulations.
• Updated recommendations on the principles of intensive insulin treatment regimens, including a more intensive form of multiple daily injections (MDIs) with new-generation faster-acting insulins and ultra-long-acting insulins, automated insulin delivery to achieve a high level of treatment personalization, better glycemia, and empowerment for people with diabetes.
• Review of the roles and rationales for new insulin analogs, biosimilars, and diabetes technology devices for insulin therapy in pediatric diabetology
• Summary of adjunctive medications used alongside insulin treatment that includes details on pramlintide, metformin, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA), and sodium-glucose cotransporter (SGLT) inhibitors.
• Key considerations with regard to access to insulin and affordability specifically innovative, multi-faceted approaches involving governments, healthcare providers, pharmaceutical companies, and advocacy groups to ensure that all persons with diabetes who need insulin can obtain it without financial hardship
For more information: ISPAD -2024 Clinical Practice Consensus Guidelines
Exclusive for Healthcare professionals only

Contact Us
We empower the fight for health and well being as a human right.
Subscribe for our latest news and updates
For adverse events reporting, please contact us on
PV.Report@evapharma.com